Skip to main content
. Author manuscript; available in PMC: 2018 Mar 29.
Published in final edited form as: Int J Biopharm Sci. 2018 Jan 2;1(1):102.

Figure 1. In vitro anti-AML therapeutic effect of blueberry extracts.

Figure 1

(A) Cellular viability was determined by MTS assay following 48-hour exposure of AML cell lines (dashed line with circles: C1498, solid line with squares: HL-60/vcr, dashed line with upside down triangles: 32D-FLT3-ITD) and a CML cell line (solid line with right side up triangles: 32D-p210-GFP) to crude blueberry extract. (B) Colony forming capacity of a poor prognosis patient AML case #329 was determined in the presence of 500 μg/ml crude blueberry extract (t-test, p=0.0245, n≥3). (C) Ficol-prepared WBC fractions of patient AML (case #651, #652, #657, #658, and #661) and patient CML (case #653) were exposed to 500 μg/ml crude blueberry extracts for 48 hours followed by flow cytometry to determine percent apoptosis (Annexin V+) in the CD45-gated blast population (t-test, p=0.0098, n=6).

HHS Vulnerability Disclosure